Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 1998

View Archived Issues

Company Profile: Cognetix

Progen expedites PI-88 cancer trials

Somerset reports results of clinical trial in major depression

La Jolla Pharmaceutical develops commercial-scale process for LJP-394

Jones Medical adopts name change to Jones Pharma

Ribozyme and Roche Bioscience enter ribozyme-based research collaboration

Antisoma and Imperial Cancer Research Technology announce collaboration

First clinical trial results reported for etomoxir in CHF

Triangle Pharmaceuticals: Q1 1998 highlights

The role of HMG-CoA reductase inhibitors in organ transplantation

New beta3-adrenoceptor agonists discovered by SmithKline Beecham

Xenova: Q1 1998 highlights

Burzynski Research Institute reports interim results from antineoplaston trial

AxyS Pharmaceuticals and Glaxo Wellcome discontinue diabetes/obesity collaboration

Habitrol transdermal nicotine patch soon to be available over the counter in Canada

Factor XIII does not show clinical efficacy in patients with ulcerative colitis

Oncologic Drugs Advisory Committee to meet early in June

Meiji Seika describes compounds with potent affinity for dopamine D4 receptors

Imidazole cytokine inhibitors prepared at SKB

NeuroSearch presents new series for schizophrenia

New respiratory therapeutics in development at Byk Gulden

Isoxazoline antibacterial agents described by Pharmacia & Upjohn

Oxis presents new antiinflammatory agents with multiple mechanisms of action

Dong Wha discloses novel antitumor agents with few side effects

BMD-188 induces tumor apoptosis in vitro and in vivo

SmithKline Beecham's Lyme disease vaccine recommended for FDA approval

ETA antagonist has protective effects in hypertensive rat model of renal damage

63% response rate obtained with RFS-2000 in pancreatic cancer; preclinical results presented at ASCO

Oral immunization against H. pylori infection appears promising in mice

FDA approves Apligraf Human Skin Equivalent for venous leg ulcers

Pfizer's NK1 antagonist CJ-11974 controls cisplatin-induced emesis in phase II study

Z-13752A, a dual ACE/NEP inhibitor that preserves the protective effects of bradykinin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...